Add-on telitacicept improves clinical response in patients with active SLE
Telitacicept used in addition to standard therapy shows promising efficacy in Chinese patients with active systemic lupus erythematosus, suggests a phase 2b trial published in the Annals of the Rheumatic Diseases.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
